Mystic Asset Management Inc. boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 126.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 174,006 shares of the biopharmaceutical company's stock after buying an additional 97,231 shares during the quarter. Pfizer makes up approximately 1.2% of Mystic Asset Management Inc.'s portfolio, making the stock its 15th largest holding. Mystic Asset Management Inc.'s holdings in Pfizer were worth $4,616,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer in the 4th quarter valued at about $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.
Pfizer Trading Down 0.4 %
Shares of PFE stock traded down $0.10 during mid-day trading on Wednesday, reaching $26.22. The company's stock had a trading volume of 26,709,469 shares, compared to its average volume of 35,765,103. The company's 50 day simple moving average is $26.21 and its 200-day simple moving average is $27.09. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $148.57 billion, a PE ratio of 18.60, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the firm posted $0.10 EPS. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
PFE has been the subject of a number of recent analyst reports. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Bank of America restated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday. Finally, UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.
Check Out Our Latest Stock Analysis on PFE
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
